IDH1-mutated relapsed or refractory AML: current challenges and future prospects

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–427. doi:10.1182/blood-2016-08-73319627895058
   PubMed Web of Science ®Google Scholar
• Megias-Vericat JE, Martinez-Cuadron D, Sanz MA, Montesinos P. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97(7):1115–1153. doi:10.1007/s00277-018-3304-y29680875
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi:10.1002/ajh.2407226016821
   PubMed Web of Science ®Google Scholar
• Bertoli S, Tavitian S, Delabesse E, Sarry A, Huguet F, Récher C. Outcome of AML patients with IDH1 or IDH2 mutations from diagnosis and refractory/relapse phase of the disease in routine practice. Blood. 2016;128(22):1718. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Dhillon S. Ivosidenib: first Global Approval. Drugs. 2018;78(14):1509–1516. doi:10.1007/s40265-018-0978-330209701
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b265119622552
   PubMed Web of Science ®Google Scholar
• Kaushansky K, Lichtman MA, Prchal JT, et al. Williams Hematology. 9th ed. New York: McGraw-Hill; 2016.
   Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–3643. doi:10.1200/JCO.2010.28.376220567020
   PubMed Web of Science ®Google Scholar
• Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116(25):5486–5496. doi:10.1182/blood-2010-02-26795520805365
   PubMed Web of Science ®Google Scholar
• Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96(12):1983–1991. doi:10.1007/s00277-017-3116-529090344
   PubMed Web of Science ®Google Scholar
• Garrett-Bakelman FE, Melnick AM, Mutant IDH. a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics. 2016;8(7):945–957. doi:10.2217/epi-2016-000827431380
   PubMed Web of Science ®Google Scholar
• Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16(9):387–397. doi:10.1016/j.molmed.2010.07.00220692206
   PubMed Web of Science ®Google Scholar
• Platt MY, Fathi AT, Borger DR, et al. Detection of dual IDH1 and IDH2 mutations by targeted next-generation sequencing in acute myeloid leukemia and myelodysplastic syndromes. J Mol Diagn. 2015;17(6):661–668. doi:10.1016/j.jmoldx.2015.06.00426331834
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348–2355. doi:10.1200/JCO.2009.27.373020368543
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa111470522417203
   PubMed Web of Science ®Google Scholar
• Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841–1855. doi:10.1016/j.celrep.2014.11.00425482556
   PubMed Web of Science ®Google Scholar
• Zhou KG, Jiang LJ, Shang Z, et al. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: A meta-analysis. Leuk Lymphoma. 2012;53(12):2423–2429. doi:10.3109/10428194.2012.69535922616558
   PubMed Web of Science ®Google Scholar
• Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation. Am J Clin Pathol. 2011;135(1):35–45. doi:10.1309/AJCPD7NR2RMNQDVF21173122
   PubMed Web of Science ®Google Scholar
• Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010;28(23):3717–3723. doi:10.1200/JCO.2010.28.228520625116
   PubMed Web of Science ®Google Scholar
• Patel KP, Barkoh BA, Chen Z, et al. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high resolution melting curve analysis. J Mol Diagn. 2011;13(6):678–686. doi:10.1016/j.jmoldx.2011.06.00421889610
   PubMed Web of Science ®Google Scholar
• Mahdieh N, Rabbani B. An overview of mutation detection methods in genetic disorders. Iran J Pediatr. 2013;23(4):375–388.24427490
   PubMed Web of Science ®Google Scholar
• Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn. 2010;12(4):487–492. doi:10.2353/jmoldx.2010.09022820431032
   PubMed Web of Science ®Google Scholar
• Gorniak P, Ejduk A, Borg K, et al. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients. Eur J Haematol. 2016;96(2):181–187. doi:10.1111/ejh.1256625891904
   PubMed Web of Science ®Google Scholar
• Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817–8822. doi:10.1073/pnas.113347010012857956
   PubMed Web of Science ®Google Scholar
• Alonso CM, Llop M, Sargas C, et al. Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics. J Mol Diagn. 2019;21(2):228-240. doi:10.1016/j.jmoldx.2018.09.009 .
   Web of Science ®Google Scholar
• Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562–5571. doi:10.1158/1078-0432.CCR-12-177323071358
   PubMed Web of Science ®Google Scholar
• Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115(14):2749–2754. doi:10.1182/blood-2009-11-25307020097881
   PubMed Web of Science ®Google Scholar
• Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122–2126. doi:10.1182/blood-2009-11-25087820538800
   PubMed Web of Science ®Google Scholar
• Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010;28(14):2356–2364. doi:10.1200/JCO.2009.27.689920368538
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2):409–412. doi:10.1182/blood-2010-12-32247921596855
   PubMed Web of Science ®Google Scholar
• Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol. 2012;5(1):5. doi:10.1186/1756-8722-5-522397365
   PubMed Web of Science ®Google Scholar
• Ravandi F, Patel K, Luthra R, et al. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012;118(10):2665–2673. doi:10.1002/cncr.2658022020636
   PubMed Web of Science ®Google Scholar
• Willander K, Falk IJ, Chaireti R, et al. Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomark Res. 2014;2(1):18. doi:10.1186/2050-7771-2-1825324972
   PubMedGoogle Scholar
• Feng JH, Guo XP, Chen YY, Wang ZJ, Cheng YP, Tang YM. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res. 2012;2(4):254–264.23226625
   PubMedGoogle Scholar
• Xu Q, Li Y, Lv N, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017;23(15):4511–4522. doi:10.1158/1078-0432.CCR-16-262828246275
   PubMed Web of Science ®Google Scholar
• Wattad M, Weber D, Döhner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31(6):1306–1313. doi:10.1038/leu.2017.2328138160
   PubMed Web of Science ®Google Scholar
• Hills RK, Gale R, Linch DC, et al. Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials [abstract]. Blood. 2018;132(Suppl 1):664.
   Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398. doi:10.1056/NEJMc171158329860938
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Dinardo CD, de Botton S, et al. Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): results of a phase 1 study [abstract plus oral communication]. J Clin Oncol. 2018;36(Suppl 15):7000. doi:10.1200/JCO.2018.36.15_suppl.7000
   Web of Science ®Google Scholar
• US Food & Drug Administration. FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation [home page on the Internet]. 2018 Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm614115.htm. Accessed 117, 2019.
   Google Scholar
• Agios Pharmaceuticals. TIBSOVO ® (Ivosidenib): US prescribing Information [home page on the internet]. 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf. Accessed 117, 2019.
   Google Scholar
• Le K, Wada R, Dai D, et al. Population pharmacokinetics of ivosidenib (AG-120) in patients with IDH1-mutant advanced hematologic malignancies [abstract]. Blood. 2018;132(Suppl 1):1394.
   Web of Science ®Google Scholar
• Birendra KC, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutan IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460–465. doi:10.1016/j.clml.2016.04.00627245312
   PubMed Web of Science ®Google Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018;4(8):1106–1110. doi:10.1001/jamaoncol.2017.469529346478
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731. doi:10.1182/blood-2017-04-77940528588020
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Mulkey F, Ward AF, et al. Incidence of differentiation syndrome with ivosidenib (IVO) and enasidenib (ENA) for treatment of patients with relapsed or refractory (R/R) isocitrate dehydrogenase (IDH)1- or IDH2-mutated acute myeloid leukemia (AML): a systematic analysis by the U.S. Food and Drug Administration (FDA) [abstract]. Blood. 2018;132(Suppl 1):288.
   Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–783. doi:10.1182/blood-2008-07-16861718945964
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: results from a phase 1 dose escalation and expansion study [abstract plus oral communication]. Blood. 2018;132(Suppl 1):561.
   Web of Science ®Google Scholar
• Stein E, Dinardo CD, Jang JH, et al. AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. J Clin Oncol. 2018;36(Suppl15):TPS7074. doi:10.1200/JCO.2018.36.15_suppl.TPS7074
   Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML) [abstract plus oral communication]. Blood. 2017;130(Suppl 1):639.
   Google Scholar
• Dinardo CD, Stein AS, Stein EM, et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML) [abstract plus poster]. J Clin Oncol. 2018;36(Suppl 15):7042. doi:10.1200/JCO.2018.36.15_suppl.7042
   Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions [abstract plus oral communication]. Blood. 2018;132(Suppl 1):560. doi:10.1182/blood-2018-99-110449.
   Web of Science ®Google Scholar
• Watts J, Baer MR, Yang J, et al. Phase 1 study of the IDH1m inhibitor FT-2102 as a single agent in patients with IDH1m acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) [abstract]. Blood. 2018;132 (Suppl 1):1453. doi: 10.1182/blood-2018-99-114263.29866817
   PubMed Web of Science ®Google Scholar
• Chopra VS, Avanzino B, Mavrommatis K, Olshen A, DiMartino J, MacBeth KJ. Functional characterization of combining epigenetic modifiers azacitidine and AG-221 in the TF-1: IDH2R140QAML model [abstract]. Cancer Res. 2016;76(Suppl 14):2280. doi:10.1158/0008-5472.CAN-16-0584
   Web of Science ®Google Scholar
• Yen K, Chopra VS, Tobin E, et al. Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model [abstract]. Cancer Res. 2018;8(Suppl 1):4956. doi:10.1158/1538-7445.AM2018-4956
   Web of Science ®Google Scholar
• Cortes JE, Watts J, Prebet T, et al. FT-2102, an IDH1m inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): results from a phase 1 study [abstract]. Blood. 2018;132 (Suppl 1):1452; doi: 10.1182/blood-2018-99-114126.
   Web of Science ®Google Scholar
• DiNardo CD, Schimmer AD, Yee KWL, et al. A phase I study of IDH305 in patients with advanced malignancies including relapsed/refractory AML and MDS that harbor IDH1R132 mutations. Blood. 2016;128(22):1073. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, et al. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma [abstract]. J Clin Oncol. 2018;36(Suppl 15):2002. doi:10.1200/JCO.2018.36.15_suppl.200229746224
   PubMed Web of Science ®Google Scholar
• Chaturvedi A, Herbst L, Pusch S, et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia. 2017;31(10):2020–2028. doi:10.1038/leu.2017.4628232670
   PubMed Web of Science ®Google Scholar
• Chaturvedi A, Gupta C, Goparaju R, et al. Synergistic activity of IDH1 inhibitor bay-1436032 with azacitidine in IDH1 mutant acute myeloid leukemia [abstract]. Blood. 2017;130(Suppl 1):1352.
   Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. doi:10.1038/nm.378825599133
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-031327520294
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407. doi:10.1002/ajh.2500029218851
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-86875230361262
   PubMed Web of Science ®Google Scholar
• Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014;42(4):247–251. doi:10.1016/j.exphem.2013.12.00124333121
   PubMed Web of Science ®Google Scholar
• Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia. Semin Hematol. 2015;52(3):165–171. doi:10.1053/j.seminhematol.2015.03.00226111463
   PubMed Web of Science ®Google Scholar
• Matre P, Velez J, Jacamo R, et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget. 2016;7(48):79722–79735. doi:10.18632/oncotarget.1294427806325
   PubMedGoogle Scholar
• Wang ES, Frankfurt O, Orford KW, et al. Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with relapsed/refractory leukemia [abstract]. Blood. 2015;126(23):2566.
   Web of Science ®Google Scholar
• Molenaar RJ, Radivoyevitch T, Nagata Y, et al. IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin Cancer Res. 2018;24(7):1705–1715. doi:10.1158/1078-0432.CCR-17-279629339439
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–327. doi:10.1038/nature1338725043048
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;3:4. doi:10.1186/s40478-014-0180-025849072
   PubMed Web of Science ®Google Scholar